Pulse Biosciences (NASDAQ:PLSE) Stock Rated Buy in New Coverage at BTIG Research

Research analysts at BTIG Research assumed coverage on shares of Pulse Biosciences (NASDAQ:PLSE) in a report released on Wednesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $70.00 price target on the stock. BTIG Research’s price objective would suggest a potential upside of 35.06% from the stock’s current price.

A number of other analysts also recently weighed in on PLSE. Wall Street Zen raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, September 6th. Canaccord Genuity Group increased their price objective on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Mizuho set a $45.00 target price on shares of Pulse Biosciences in a research note on Monday, August 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Pulse Biosciences has a consensus rating of “Buy” and a consensus target price of $50.20.

Pulse Biosciences Stock Down 0.3%

Shares of NASDAQ PLSE traded down $0.15 during trading on Wednesday, reaching $51.83. The company had a trading volume of 666,868 shares, compared to its average volume of 386,794. The stock has a market cap of $3.67 billion, a P/E ratio of -43.92 and a beta of 1.63. The company’s fifty day moving average price is $44.45 and its 200-day moving average price is $30.99. Pulse Biosciences has a 12 month low of $12.56 and a 12 month high of $58.90.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The company had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. As a group, equities analysts predict that Pulse Biosciences will post -1.29 earnings per share for the current year.

Insider Buying and Selling at Pulse Biosciences

In other Pulse Biosciences news, COO Liane Teplitsky bought 1,001 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were bought at an average price of $49.95 per share, for a total transaction of $49,999.95. Following the acquisition, the chief operating officer directly owned 4,095 shares of the company’s stock, valued at approximately $204,545.25. The trade was a 32.35% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders have bought 4,095 shares of company stock valued at $199,931. Corporate insiders own 74.00% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

A number of hedge funds have recently added to or reduced their stakes in the stock. Osterweis Capital Management Inc. bought a new position in shares of Pulse Biosciences in the second quarter valued at approximately $28,000. Jupiter Topco LLC bought a new stake in Pulse Biosciences during the second quarter worth $241,000. GSA Capital Partners LLP purchased a new stake in Pulse Biosciences in the 2nd quarter valued at $290,000. Legal & General Group Plc purchased a new stake in Pulse Biosciences in the 2nd quarter valued at $395,000. Finally, Cetera Investment Advisers bought a new position in Pulse Biosciences during the 1st quarter valued at $387,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a medical technology company developing proprietary bioelectric therapies based on its Nano-Pulse Stimulation technology. The platform delivers ultrashort electrical pulses designed to affect targeted cells while limiting thermal damage to surrounding noncellular tissue.

The company’s primary product is the CellFX System, which is designed to deliver Nano-Pulse Stimulation treatments for certain dermatological conditions. Pulse Biosciences is also developing additional applications for its technology in areas including cardiac procedures and other medical specialties.

Pulse Biosciences was founded in 2014 and is headquartered in Hayward, California.